Skip to main content
. 2008 May;24(5):363–368. doi: 10.1016/s0828-282x(08)70597-x

Figure 2).

Figure 2)

Estimated number of cardiovascular (CV) events among 2.2 million high-risk Canadians over the next 10 years. Current care includes current levels of statin, acetylsalicylic acid and angiotensin-converting enzyme inhibitor use. Triple therapy assumes combination use of statin, acetylsalicylic acid and angiotensin-converting enzyme inhibitor therapy